DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactResults

Marksans Pharma Limited — Outcome of Board Meeting

NSE 1 hr ago·12 Aug 2026, 6:55 am

Marksans Pharma

Marksans Pharma has announced its unaudited financial results for the quarter that ended on June 30, 2026. The company has submitted these results to the stock exchange, which means investors now have access to the latest performance data for the period.

For investors, this update is important as it provides a snapshot of the company's operational health and financial position during the quarter. It helps in tracking the company's progress against its past performance and market expectations.

Moving forward, investors should focus on the key metrics within the results, such as revenue growth, profit margins, and any commentary on future outlook. This will help in assessing the company's trajectory and making informed decisions.